semaglutide blog Before and After: Real Weight Loss Results What Is Semaglutide? Here's What

Statistical analysis We performed MR analysis using the TwoSampleMR R package (version 0.5.8)

Feel confident moving forward Ask questions, explore next steps, and take action without pressure

Semaglutide for the treatment of type 2 diabetes mellitus (TA772)

May 19, 2022

Key findings from OASIS 4 Double-blind, placebo-controlled, 64-week, phase 3 trial (N=307) Mean weight loss: 13.6% (semaglutide) vs 2.2% (placebo) 5% weight loss in 79.2% (semaglutide) vs 31.1% (placebo) Improvements in physical functioning and cardiometabolic markers Serious adverse events were lower in the semaglutide group (3.9% vs 8.8%) This could be a key player particularly among patients who are needle-averse, travel often, or seek simpler dosing options